Histomorphometric effect of six month treatment with oral Risedronate in patients with multiple myeloma.
Cohen-Solal
M E
ME
Inserm U349, Centre Viggo Petersen, Lariboisiere Hospital, Paris, France.
Roux
C
C
Valentin-Opran
A
A
Dougados
M
M
Amor
B
B
De Vernejoul
M C
MC
D000284:Administration, Oral; D000368:Aged; D001862:Bone Resorption / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000473:pathology; D000068296:Risedronic Acid; D013997:Time Factors
D000068296:Risedronic Acid; D012968:Etidronic Acid